NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001146

Registered date:01/06/2008

Phase II study with tacrolimus to prevent GVHD for reduced-intensity peripheral blood stem cell transplantation from an HLA-identical related donor

Basic Information

Recruitment status Complete: follow-up continuing
Health condition(s) or Problem(s) studiedAcute leukemia, Chronic leukemia, Myelodysplastic syndrome, Malignant lymphoma, Adult T cell leukemia/lymphoma
Date of first enrollment2008/07/01
Target sample size26
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Use tacrolimus and short-term methotrexate as a GVHD prophylaxis

Outcome(s)

Primary OutcomeIncidence of grade II-IV acute GVHD at 100 days after PBSCT
Secondary OutcomeIncidence of chronic GVHD, overall survival rate at 2 years, nonrelapse mortality rate at 2 years, relapse rate at 2 years, treatment-associated toxicity, term to hematopoietic recovery

Key inclusion & exclusion criteria

Age minimum16years-old
Age maximum65years-old
GenderMale and Female
Include criteria
Exclude criteria(1)Positive for HIV antibody andor HBs antigen (2)T cell depleted transplantation (3)Pregnant or during breast feeding (4)Uncontrolled psychiatric disease (5)Uncontrolled active infection (6)Allergic history to drugs used in the present conditioning regimen or GVHD prophylaxis regimen (7)A history of intravenous chemotherapy within 21 days before transplantation (8)Cases that physicians judged as inappropriate

Related Information

Contact

public contact
Name Yoshihiro Inamoto
Address 65 Tsurumai, Showa-ku, Nagoya, Aichi, Japan Japan
Telephone 052-744-2145
E-mail yinamoto@med.nagoya-u.ac.jp
Affiliation Nagoya University Graduate School of Medicine Department of Hematology and Oncology
scientific contact
Name Koichi Miyamura
Address 3-35 Michishita-cho, Nakamura-ku, Nagoya, Aichi, Japan Japan
Telephone 052-481-5111
E-mail
Affiliation Japanese Red Cross Nagoya First Hospital Department of Hematology